As the stock of MannKind Corporation (NASDAQ:MNKD) tumbled Wednesday and Thursday, outpacing general stock market declines, while a Forbes report, citing a technical indicator, says it is oversold and might be time for a bounce back. MannKind’s new wonder drug is a dud: Tourbillon MannKind Corporation (NASDAQ:MNKD) had been the subject of short speculation from the hedge fund Tourbillon Capital Partners, first reported by CNBC July 25. Tourbillon had charged that Mannkind’s new wonder drug, considered a cause for the recent dramatic rise in the stock price, is really a dud due to health risks and pricing issues. Mannkind was…
Mannkind Corporation (MNKD) Oversold Based on One Indicator
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.
Comments are closed.